A polypeptide drug and its application in preventing or treating abdominal aortic aneurysm
By developing polypeptide drugs containing CRGDQG and auxiliary membrane penetration sequences, competitively binding to signalin 7A and ITGB1 receptors, the targeting problem of abdominal aortic aneurysm treatment in the prior art was solved, significantly slowing down the expansion and rupture of abdominal aortic aneurysm risk, providing a safe and effective prevention and treatment plan.
Patent Information
- Application Number
- CN202411267695.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-11
AI Technical Summary
The existing technology lacks effective targeted drugs in the prevention and treatment of abdominal aortic aneurysms, resulting in early expansion and rupture of abdominal aortic aneurysms, leading to fatal cardiovascular collapse. The existing drug treatment can only alleviate symptoms, and the surgical treatment is high and costly. High and no drugs can effectively target abdominal aortic aneurysms.
A polypeptide drug containing CRGDQG sequence and auxiliary membrane penetration sequence was developed to inhibit the synthesis of smooth muscle cells and slow the expansion of abdominal aortic aneurysms by competitively binding to signalin 7A (SEMA7A) and ITGB1 receptor.
By targeted knockdown or inhibiting SEMA7A expression, the development of abdominal aortic aneurysm is significantly slowed down, the maximum diameter and lesion of abdominal aortic aneurysm is reduced, the risk of dilation and rupture of abdominal aortic aneurysm is weakened, and a safe, Effective prevention and treatment options.
Smart Images

Figure CN118772296B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a polypeptide drug and application thereof in preventing or treating abdominal aortic aneurysm, belonging to the technical field of biomedicine. Background Art
[0002] Abdominal aortic aneurysm (AAA) is characterized by abnormal expansion of the abdominal aorta exceeding 1.5 times the diameter of the normal artery. It is a common, insidious, and highly lethal critical cardiovascular disease. Due to its continuous expansion, the abdominal aortic aneurysm will eventually rupture and cause death. At present, clinically, conservative drug treatment can be adopted for abdominal aortic aneurysms with a diameter of less than 4 cm, mainly through drug control of blood lipids and blood pressure. Among them, lipid-lowering drugs such as statins can control lipid metabolism and stabilize atherosclerotic plaques, and antihypertensive drugs such as beta-blockers, calcium ion antagonists, and ACEI (angiotensin converting enzyme inhibitors) can control blood pressure and heart rate for antihypertensive treatment. However, when the diameter of the abdominal aortic aneurysm reaches 4-5 cm or more, surgery or interventional treatment is required. Surgery mainly removes the abdominal aortic aneurysm tissue and replaces it with an artificial blood vessel, while interventional treatment performs intravascular repair and implants a vascular stent at the aneurysm site to prevent aneurysm rupture and cause massive bleeding.
[0003] However, the clinical use of antihypertensive and lipid-lowering drugs are only conservative treatments to relieve symptoms. They can reduce the growth rate of abdominal aortic aneurysms in the early stages of the disease. However, with age, abdominal aortic aneurysms can continue to expand until they rupture. At the same time, although surgical treatments such as endovascular repair of abdominal aortic aneurysms have made technological advances, surgical treatments are risky and expensive, and implanting abdominal aortic aneurysm stents may cause side effects such as vascular stenosis / occlusion and dysfunction. Currently, no drug has been proven to effectively target the development of abdominal aortic aneurysms, and more than 50% of patients with AAA rupture die of sudden cardiovascular collapse before arriving at the hospital. Therefore, it is urgent to explore the molecular mechanisms of the onset of abdominal aortic aneurysms and develop drugs that target the prevention and treatment of abdominal aortic aneurysms. Summary of the invention
[0004] In order to solve the above problems, the present invention provides a polypeptide that can be applied to drugs for preventing and treating abdominal aortic aneurysm formation / rupture. The development of abdominal aortic aneurysm can be significantly inhibited by supplementing the polypeptide.
[0005] The first object of the present invention is to provide a polypeptide for preventing or treating abdominal aortic aneurysm, wherein the polypeptide contains the sequence shown in SEQ ID NO.2 and a sequence for assisting membrane penetration.
[0006] Furthermore, the sequence for assisting membrane penetration includes at least one of the following:
[0007] (1) The sequence for assisting membrane penetration comprises an amino acid sequence rich in positive charges;
[0008] (2) The sequence for assisting membrane penetration comprises an amino acid sequence that complies with the CendR rule;
[0009] (3) The sequence for assisting membrane penetration contains cysteine;
[0010] (4) The sequence for assisting membrane penetration contains the sequence shown in SEQ ID NO. 3 or a sequence with a homology of not less than 80% thereto.
[0011] Furthermore, the amino acid sequence of the polypeptide is shown in SEQ ID NO. 1. Compared with antibodies with high R&D costs, long production cycles, high storage requirements and easy inactivation, the polypeptide drugs of the present invention have the advantages of low synthesis costs, short production cycles, strong stability and few side effects.
[0012] The second object of the present invention is to provide a polynucleotide encoding the above polypeptide.
[0013] The third object of the present invention is to provide a recombinant expression vector carrying the above polynucleotide.
[0014] Furthermore, the recombinant expression vector includes but is not limited to a recombinant plasmid, a recombinant adeno-associated virus vector, DNA, RNA, etc.
[0015] The fourth object of the present invention is to provide a recombinant cell containing the above recombinant expression vector.
[0016] Furthermore, the host cell of the recombinant cell may be a prokaryotic cell or a eukaryotic cell, such as a human cell or a microorganism that can be used for polypeptide production.
[0017] The fifth object of the present invention is to provide a recombinant protein containing the above polypeptide.
[0018] Furthermore, the recombinant protein contains a tag sequence that assists expression and / or purification.
[0019] Preferably, the tag sequence includes but is not limited to an Fc tag, an HA tag or a 6xHis tag.
[0020] The sixth object of the present invention is to provide the use of the polypeptide, polynucleotide, recombinant expression vector, recombinant cell, and recombinant protein in the preparation of a drug for preventing or treating abdominal aortic aneurysm.
[0021] The seventh object of the present invention is to provide a pharmaceutical composition containing the above-mentioned polypeptide, polynucleotide, recombinant expression vector, recombinant cell or recombinant protein.
[0022] Furthermore, the pharmaceutical composition also contains a pharmaceutically acceptable carrier, which includes but is not limited to a filler, an excipient, a stabilizer, a diluent, a binder, a lubricant, a surfactant, and the like.
[0023] In addition, the present invention also claims to protect another drug for treating abdominal aortic aneurysm, which can target and knock down, knock out or inhibit the expression of semaphorin 7A (SEMA7A) in smooth muscle cells, and the drug contains a substance that knocks out SEMA7A and a substance that targets smooth muscle cells.
[0024] Furthermore, substances for knocking down or knocking out the SEMA7A encoding gene include but are not limited to shRNA, miRNA, sequences packaged by lentivirus, CRISPR-related molecules, etc.
[0025] Beneficial effects of the present invention:
[0026] There are not many peptide drugs used in clinical practice, and there has been no report on peptide drugs for abdominal aortic aneurysm. Sema7a Knockout can slow down the expansion of abdominal aortic aneurysm, and subsequent mechanism studies have clarified that SEMA7A protein promotes the transformation of smooth muscle cells from contractile to synthetic by binding to the smooth muscle cell surface receptor ITGB1, mediating the occurrence and development of abdominal aortic aneurysm. Based on the above findings, the present invention connects the sequence CRGDQG with a cell-penetrating peptide, and for the first time provides a polypeptide drug that can be used to prevent and treat the formation / rupture of abdominal aortic aneurysm. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is the effect of smooth muscle cell SEMA7A on the formation of abdominal aortic aneurysm in mice; A is smooth muscle cell Sema7a Schematic diagram of the construction of the knockout mouse abdominal aortic aneurysm model, B is smooth muscle cells Sema7a Abdominal aortic aneurysms of knockout mice were photographed in vivo. C is a statistical diagram of the maximum diameter of abdominal aortic aneurysms of mice. N≥3, data are presented as mean ± standard error.
[0028] Figure 2 RT-PCR was used to detect the expression of SEMA7A receptor on the surface of smooth muscle cells.
[0029] Figure 3 Ultrasound angiography of the abdominal aorta of mice administered with SEMA7A polypeptide or control polypeptide and simple calcium phosphate modeling. The dotted line marks the vascular structure.
[0030] Figure 4The administration of SEMA7A polypeptide reduces the maximum diameter of abdominal aortic aneurysm in mice; A is a photograph of abdominal aortic aneurysm in mice administered SEMA7A polypeptide or control polypeptide and normal calcium phosphate modeling, and B is a statistical chart of the maximum diameter of abdominal aortic aneurysm in mice. N≥3, data are presented as mean ± standard error.
[0031] Figure 5 The administration of SEMA7A peptide attenuated the degree of abdominal aortic aneurysm lesions in mice induced by calcium phosphate; A is the morphological structure and elastic fiber of abdominal aortic aneurysm tissue in mice after administration of SEMA7A peptide, detected by HE staining and Victoria blue staining, and B is the statistics of elastic fiber degradation grade. N≥3, data are presented as mean ± standard error.
[0032] Figure 6 Immunoblotting was used to detect the expression changes of OPN, a synthetic marker of smooth muscle cells, and Calponin1, a contractile marker, after co-incubation of mouse smooth muscle cells with SEMA7A polypeptide or control polypeptide. DETAILED DESCRIPTION
[0033] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0034] Explanation of terms involved in the following embodiments:
[0035] Generally speaking, peptide drugs include the following: (1) hormone peptides and their derivative drugs, mainly including insulin and its analogs, somatostatin, oxytocin, growth hormone-releasing hormone, gonadotropin-releasing hormone, calcitonin, etc.; (2) natural peptide drugs, natural peptide products derived from humans, animals, plants, microorganisms, etc.; (3) peptide vaccines, which are subunit vaccines made of peptides. By simulating the epitope sequence of antigens, they can be used as immunogens to stimulate the body to produce immune responses; (4) PDC (peptide-drug conjugates) peptide drugs, which are formed by covalently bonding peptides and drugs through linkers, retaining the function and biological activity of peptides, and also using the cleavable properties of linkers to responsively release drugs.
[0036] In the present invention, "polypeptide", "polypeptide drug" and the like have the same meaning and can be used interchangeably, and all refer to molecules composed of amino acids as basic units. The molecular weight of polypeptides is generally below 10 KDa, which is between chemical small molecule drugs and biological preparations: compared with biological preparations (such as antibodies, therapeutic proteins, etc.), they have similar modes of action, but polypeptides have lower immunogenicity, and because they can be chemically synthesized, their production costs are also lower; compared with chemical small molecule drugs, polypeptides have a larger molecular weight, can effectively inhibit protein-protein interactions, have higher selectivity and specificity, and have lower concentrations and side effects.
[0037] The "polypeptide" or "polypeptide drug" of the present invention is a class of compounds formed by connecting multiple amino acids through peptide bonds, and the connection method is the same as that of proteins. However, the polypeptide drug of the present invention is different from traditional antibody drugs: for example, therapeutic antibodies directly achieve treatment through neutralization, competitive inhibition / antagonism, etc., and antibody-drug conjugates (ADC) are a drug formed by coupling compound drugs with antibodies through a linker. The antibody part of ADCs specifically binds to the antigen and releases compound drugs with killing effects to kill target cells. However, antibody drugs are subject to certain restrictions in application, and a large part of the reason is that it is difficult for antibodies to pass through the capillary endothelial layer and the extracellular space to reach the target location. The preferred polypeptide of the present invention is only a short peptide of more than a dozen amino acids, which does not have the limitations of the above-mentioned antibody drugs, and has the characteristics of low synthesis difficulty and low synthesis cost.
[0038] The polypeptide or polypeptide drug of the present invention contains a CRGDQG sequence (SEQ ID NO. 2), which may effectively inhibit the function of SEMA7A by competitively binding with ITGB1 (β1 integrin) of SEMA7A protein (semaphorin 7A), and is the minimum functional unit for the polypeptide or polypeptide drug of the present invention to prevent or treat abdominal aortic aneurysm.
[0039] In the present invention, in addition to the above-mentioned minimum functional unit, the polypeptide or polypeptide drug also contains a sequence for assisting membrane penetration, which can be modified at the N-terminus or C-terminus of the minimum functional unit. Cell-penetrating peptides can assist SEMA7A polypeptides to penetrate the membrane from the endothelial cell layer of the vascular lumen and bind to ITGB1 on the surface of smooth muscle cells, thereby inhibiting the phenotypic transformation of smooth muscle cells caused by the binding of SEMA7A protein to ITGB1. In the present invention, "sequences for assisting membrane penetration", "cell-penetrating peptides" and the like have the same meaning and can be used interchangeably.
[0040] Preferably, the sequence used to assist in membrane penetration is a positively charged amino acid sequence, that is, a sequence that introduces positively charged amino acids such as arginine and / or lysine. Such sequences can interact with negatively charged phospholipid head groups on the cell membrane, thereby enhancing the membrane penetration ability of the polypeptide or polypeptide drug of the present invention. Of course, the sequence used to assist in membrane penetration can also be a polypeptide that complies with the CendR rule, that is, a sequence that complies with the [R / K]XX[R / K] rule (R is arginine, K is lysine, and X is any amino acid) is introduced.
[0041] More preferably, the sequence for assisting membrane penetration contains cysteine. In this case, disulfide bond modification of cysteine (Cys) in the minimum functional unit and cysteine in the cell-penetrating peptide can stabilize the spatial structure of the peptide chain and achieve long-term blood circulation in the body. Therefore, in one embodiment of the present invention, the cell-penetrating peptide is designed as CGKRK (SEQ ID NO.3). Of course, those skilled in the art know that other cell-penetrating peptides obtained according to the above design ideas can also achieve the above functions.
[0042] The present invention also provides a polynucleotide encoding the above polypeptide. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded.
[0043] The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence encoding only a mature polypeptide; a coding sequence of a mature polypeptide and various additional coding sequences; a coding sequence of a mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0044] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may include a polynucleotide further including additional coding and / or non-coding sequences.
[0045] The polypeptide of the present invention can be directly obtained by chemical methods such as solid phase synthesis. Of course, it is not excluded that the polypeptide can be obtained by gene transcription and translation using biosynthesis.
[0046] The full-length nucleotide sequence of the present invention or its fragments can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by synthesizing multiple small fragments first and then connecting them. In addition, the coding sequence of the heavy chain and the expression tag (such as 6His) can be fused together to form a fusion protein.
[0047] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the proliferated host cells by conventional methods. The biomolecules (nucleic acids, proteins, etc.) involved in the present invention include biomolecules in isolated form.
[0048] At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.
[0049] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0050] Host cells can be prokaryotic cells, such as bacterial cells; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; animal cells such as CHO, COS7, 293 cells, etc.
[0051] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be carried out by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0052] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. When the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0053] The recombinant polypeptide in the above method can be expressed in the cell or on the cell membrane or secreted outside the cell. If necessary, the protein of the recombinant can be separated and purified by various separation methods using its physical, chemical and other characteristics. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and the combination of these methods.
[0054] The polypeptide of the present invention can be used alone or in combination or coupled with a detectable marker, etc. Detectable markers for diagnostic purposes include, but are not limited to, fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing a detectable product.
[0055] Pharmaceutical composition
[0056] The present invention also provides a composition. Preferably, the composition is a pharmaceutical composition, which contains the above-mentioned polypeptide or its active fragment or its fusion fragment, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, and the pH value may vary with the properties of the formulated substance, and the technician can adjust it as needed. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intraperitoneal, intravenous, or topical administration.
[0057] The pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned polypeptide of the present invention and a pharmaceutically acceptable carrier. Such carriers include (but are not limited to): fillers, excipients, stabilizers, diluents, adhesives, lubricants, surfactants or combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The amount of active ingredient administered is a therapeutically effective amount. In addition, the polypeptide of the present invention can also be used with other therapeutic agents.
[0058] When using a pharmaceutical composition, a safe and effective amount of the drug is administered to an individual. The specific dosage should also take into account factors such as the route of administration and the patient's health condition, which are all within the skills of a skilled physician.
[0059] Example 1: Knockout of smooth muscle cell Sema7a attenuates the formation of abdominal aortic aneurysm
[0060] (1) Use Sema7a flox / flox Mice and Myh11-CreER T2 Crossbreeding of mice (smooth muscle-specific Cre mice) to construct smooth muscle cell Sema7a Conditional knockout mice ( Figure 1 Middle A).
[0061] (2) The mouse was anesthetized with 1.2% tribromoethanol solution, and then fixed on a surgical board for abdominal hair removal. A 1.5-2 cm incision was made in the mouse's abdomen using microscissors, and the intestines and other organs were wrapped with gauze soaked in saline and slowly moved to one side to expose the abdominal aorta, and then a sterilized abdominal dilator of appropriate size was placed.
[0062] (3) Use a cotton swab to slowly separate the fat and connective tissue around the abdominal aorta. Then use ophthalmic forceps to grab a thin piece of cotton wool to slowly separate the tissue adhered to the abdominal aorta, and completely free the blood vessels from the lower segment of the renal artery to the bifurcation of the iliac artery.
[0063] (4) After using dry gauze to absorb the peritoneal fluid, the abdominal aorta was incubated with a piece of gauze (0.5 cm × 0.3 cm) soaked in 0.5 M CaCl2 for 10 min, and then incubated with a piece of gauze of equal length soaked in 10× PBS for 5 min.
[0064] (5) Remove the gauze incubated on the aorta and rinse the incubation area with normal saline containing 2% double antibody. After aspirating the flushing solution with a cotton swab, remove the gauze wrapped around the organ.
[0065] (6) After observing that there is no active bleeding, suture the peritoneum and skin with a 4-0 suture needle, apply iodine to the wound, and gently massage both sides of the abdomen. Use a heating pad to maintain the body temperature of the mouse until it wakes up, put it in a mouse cage, and allow it to eat and drink freely. After 2 weeks, the entire aorta of the mouse was isolated and photographed ( Figure 1 B) and statistics ( Figure 1 C) After smooth muscle cells were found Sema7a Conditional knockout reduces the maximum diameter of abdominal aortic aneurysms in mice, confirming the smooth muscle cell origin Sema7a Can promote the formation of abdominal aortic aneurysms in mice.
[0066] Example 2: Synthesis and purity detection of SEMA7A polypeptide
[0067] SEMA7A can mediate the activation of downstream signaling pathways through membrane surface receptor proteins ITGB1 (β1 integrin) and PLXNC1 (plexin C1), thus playing an important role in various types of cells. Therefore, in order to study which receptor SEMA7A mainly acts through, we used RT-PCR to detect the expression of ITGB1 and PLXNC1 in human aortic smooth muscle cells and found that human aortic smooth muscle cells expressed ITGB1 but not PLXNC1 ( Figure 2 ). This result suggests that SEMA7A may act through the ITGB1 receptor.
[0068] Therefore, we designed two peptides based on the potential binding region of SEMA7A and ITGB1 on the surface of smooth muscle cells, namely SEMA7A peptide and control peptide, both with a length of 11 amino acids. The sequence information is as follows:
[0069] SEMA7A polypeptide: CGKRKCRGDQG (SEQ ID NO.1)
[0070] Control peptide: CGKRKGCQRDG
[0071] The above peptides were synthesized by solid phase peptide synthesis. The specific steps are as follows: 1) 5g of 2-chlorotrityl resin was placed in a reaction tube, dichloromethane (DCM) was added, and the resin was swollen by shaking for 30 minutes. 2) The solvent was removed by sand core filtration, and amino acid connection was performed by adding 1.5 times molar excess of Fmoc-L-Pro-OH amino acid (Fmoc-L-proline) and 10 times molar excess of N,N-diisopropylethylamine (DIEA). 3) A certain amount of methanol was added to the reaction solution to block the excess reaction sites. 4) Deprotection was performed using 20% piperidine / DMF solution (dimethylformamide / piperidine mixed solution). 5) The piperidine solution was removed, and one drop each of ninhydrin, potassium cyanide (KCN), and phenol solution was added, and peptide detection was performed after heating for 5 minutes. 6) After washing with DMF (10mL / g) and methanol (10mL / g), condensation reaction was performed using peptide coupling reagent HBTU. 7) Repeat steps 4-6 to connect the amino acids in the sequence from right to left. 8) After the last amino acid is deprotected, wash with DMF, methanol, DCM and dry. 9) Cut the peptide from the resin and blow dry and wash to obtain the crude peptide.
[0072] HPLC purification of peptides, the specific steps are: 1) After the crude peptide is dissolved in water, hydrogen peroxide is added to make it alkaline and the mass spectrometer is used to detect whether it is completely oxidized. 2) The crude product is analyzed by analytical HPLC, and the collected samples are sampled for purity and mass spectrometry identification.
[0073] Peptide purity analysis: Take 1 mg of white powdered peptide and dissolve it in water. According to the length of the sequence, select the appropriate acetonitrile gradient for analysis.
[0074] The results showed that the purity of the synthesized SEMA7A peptide and the control peptide reached more than 95%, and could be used for subsequent animal and cell experiments.
[0075] Example 3: Treatment of abdominal aortic aneurysm mice with SEMA7A polypeptide
[0076] (1) Ten-week-old mice were randomly divided into three groups, namely, calcium phosphate group, calcium phosphate + control peptide group, and calcium phosphate + SEMA7A peptide group.
[0077] (2) SEMA7A peptide and control peptide were injected into mice via the tail vein at a dose of 25 mg / kg according to body weight.
[0078] (3) One day after the tail vein injection, the mice were anesthetized and the calcium phosphate-induced mouse abdominal aortic aneurysm model was constructed.
[0079] (4) The mice that have recovered normal activities are sent to the animal room and injected with peptides every three days.
[0080] (5) Two weeks later, the mice underwent small animal ultrasound and the entire aorta was isolated and photographed.
[0081] (6) Small animal ultrasound angiography was performed on three groups of model mice to observe the formation of abdominal aortic aneurysms in vivo. The results showed that the administration of control peptides failed to slow down the expansion of abdominal aortic aneurysms induced by calcium phosphate, while the administration of SEMA7A peptides could reduce the expansion of abdominal aortic aneurysms ( Figure 3 ).
[0082] (7) After euthanasia, the three groups of mice were perfused through the heart and fixed with 4% paraformaldehyde to isolate the entire aorta of the mice. The formation of abdominal aortic aneurysms was observed by stereomicroscope photography. The results also showed that administration of SEMA7A peptide could reduce the expansion of abdominal aortic aneurysms ( Figure 4 ).
[0083] Example 4: SEMA7A polypeptide can slow down the degradation of elastic fibers in the vascular wall of abdominal aortic aneurysms in mice induced by calcium phosphate
[0084] (1) HE staining of abdominal aortic aneurysm tissues of the three groups of mice revealed that the vascular walls of the mice given the control peptide after calcium phosphate modeling were thickened, the lumen was dilated, and there was a large infiltration of inflammatory cells. However, after the administration of SEMA7A peptide, the vascular wall thickness of the abdominal aortic aneurysm tissues of the mice was relatively uniform, and the cells were arranged relatively neatly ( Figure 5 Middle A), indicating that SEMA7A peptide can alleviate the severity of abdominal aortic aneurysm lesions induced by calcium phosphate in mice.
[0085] (2) After staining the abdominal aortic aneurysm tissues of the three groups of mice using Victoria blue staining (VB staining), it was found that the average degradation grade of the elastic fibers in the abdominal aortic aneurysm vascular wall of the mice given the control peptide group was 3.17, while the elastic fiber breakage was weakened after the administration of SEMA7A peptide, with an average degradation grade of 2.17 ( Figure 5 Middle B).
[0086] Example 5: SEMA7A polypeptide can inhibit phenotypic transformation of mouse smooth muscle cells
[0087] (1) Primary mouse smooth muscle cells were plated at a cell density of 300,000 / mL.
[0088] (2) Mouse primary smooth muscle cells were pre-incubated with 50 μM SEMA7A peptide and control peptide for 12 hours.
[0089] (3) After stimulating the cells with 0.05 M calcium phosphate for 30 min, 50 μM SEMA7A peptide or control peptide was added and incubated for 48 h.
[0090] (4) Lyse the smooth muscle cells using protein lysis buffer, and then perform immunoblotting to detect smooth muscle cell contractile markers Calponin1 The expression of calcitonin-1 and the synthetic marker OPN (osteopontin) was detected.
[0091] (5) Western blotting revealed that SEMA7A peptide could attenuate the expression of OPN, a synthetic marker of mouse smooth muscle cells, induced by calcium phosphate, and promote the expression of contractile markers of smooth muscle cells. Calponin1 Express( Figure 6 ).
[0092] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A polypeptide for treating abdominal aortic aneurysm, characterized in that: The amino acid sequence of the polypeptide is shown in SEQ ID NO.
1.
2. A polynucleotide encoding the polypeptide of claim 1.
3. A recombinant expression vector carrying the polynucleotide according to claim 2.
4. A recombinant cell containing the recombinant expression vector according to claim 3.
5. A recombinant protein containing the polypeptide according to claim 1.
6. Use of the polypeptide according to claim 1, the polynucleotide according to claim 2, the recombinant expression vector according to claim 3, the recombinant cell according to claim 4 or the recombinant protein according to claim 5 in the preparation of a drug for treating abdominal aortic aneurysm.
7. A pharmaceutical composition, characterized in that Containing the polypeptide according to claim 1, the polynucleotide according to claim 2, the recombinant expression vector according to claim 3, the recombinant cell according to claim 4 or the recombinant protein according to claim 5.
8. A drug for treating abdominal aortic aneurysm, characterized in that: The medicine contains the pharmaceutical composition according to claim 7.
Citation Information
Patent Citations
Application of LKB1 gene in preparation of anti-abdominal-aortic-aneurysm drugs
CN109602918A
Application of Gs alpha gene in preparation of medicament for resisting abdominal aortic aneurysm
CN109652542A
